Phenol
CAS 108-95-2
Phenol (CAS 108-95-2) is a Phase 4 pharmaceutical compound with 12 bioactivity targets and 142 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Ki | 14091.525423728814 nM | 59 | - |
| - | AC50 | 27404.20909090909 nM | 33 | - |
| - | IC50 | 42399.0775 nM | 7 | - |
| - | Potency | 453763.1875 nM | 6 | - |
| - | Kd | 61900 nM | 3 | - |
| - | MIC | 96 ug.mL-1 | 2 | - |
| Carbonic anhydrase 2 Enzyme |
Ki | 5.26 | - | Homo sapiens |
| Carbonic anhydrase 1 Enzyme |
Ki | 5 | - | Homo sapiens |
| Carbonic anhydrase 4 Enzyme |
Ki | 5.02 | - | Homo sapiens |
| Carbonic anhydrase 9 Enzyme |
Ki | 5.06 | - | Homo sapiens |
| Carbonic anhydrase 12 Enzyme |
Ki | 5.04 | - | Homo sapiens |
| Carbonic anhydrase 3 Enzyme |
Ki | 5.57 | - | Homo sapiens |
| Carbonic anhydrase 14 Enzyme |
Ki | 4.94 | - | Homo sapiens |
| Endolysin Enzyme |
Kd | 4.04 | - | Enterobacteria phage T4 |
| Carbonic anhydrase 15 Enzyme |
Ki | 4.98 | - | Mus musculus |
| Carbonic anhydrase Enzyme |
Ki | 4.76 | - | Candida albicans (strain SC5314 / ATCC MYA-2876) |
| Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase Enzyme |
Ki | 4.1 | - | Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) |
| Carbonic anhydrase 2 Enzyme |
Ki | 4.59 | - | Cryptococcus neoformans var. grubii |
| Carbonic anhydrase Enzyme |
Ki | 4.86 | - | Dicentrarchus labrax |
| Beta-carbonic anhydrase 1 Enzyme |
Ki | 4.19 | - | Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Cystitis-like symptom | 4 | 33.376 | 10050687 |
| Urticaria pressure | 3 | 22.39 | 10052572 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| PHENOL | 33290 | SU | MTHSPL |
| Phenol | 33290 | SU | MTHSPL |
| phenol | 33290 | SU | MTHSPL |
| phenol | 33290 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Phenol used for in pharmaceutical contexts?
Phenol (CAS 108-95-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Phenol?
Phenol has 142 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Cystitis-like symptom, Urticaria pressure, Abdominal discomfort, Abdominal pain upper, Acute kidney injury. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Phenol also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Phenol with EU status "restricted".
What clinical phase is Phenol in?
Phenol is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Phenol?
Phenol has 20 bioactivity rows in this page query. Rendered target entries include Carbonic anhydrase 2, Carbonic anhydrase 1, Carbonic anhydrase 4, Carbonic anhydrase 9, Carbonic anhydrase 12.